Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib + NHA in mCSPC (EvoPAR-Prostate01)
NCT06120491Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of saruparib in prostate cancer (PCa), sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06120491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120491.